For reference sake I'll provide an annotated chart of IMU illustrating how their SP reacted to developments of their phase one clinical trial.
IMU re-rated from ~5c to 14c ahead of their first patient dose (1 Dec 2020), the SP continued to base for approx. 4 months until the final patient was dosed (7th April 2021) which kicked off the next leg of the re-rating.
Keeping in mind that at its peak, IMU MCAP was north of AUD$3B and even now sits just shy of AUD$1B.
I can appreciate that a direct comparison cannot easily be made between the two companies but to the extent this provides some reference on how the market may respond to PYC's commencement of clinical trials it may be considered helpful.
Should be plenty of upside from here on out, seems just a matter of when.
PYC Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)